A Dendritic Cell-Nanogel Conjugate for Tumor-Draining Lymph Node-Specific PD-L1 Blockade

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Targeted blockade of immune checkpoints in tumor-draining lymph nodes (TDLNs) can enhance immune checkpoint blockade (ICB) therapy.
• Challenges include limited delivery of inhibitors to TDLNs and insufficient T cell priming.

Purpose of the Study:

• To develop a novel dendritic cell (DC)-based strategy for targeted delivery of ICB antibodies to TDLNs.
• To enhance systemic antitumor immunity by combining DC vaccination with ICB therapy.

Main Methods:

• Conjugating anti-PD-L1 antibody nanogels with DCs pre-treated with tumor antigens.
• Utilizing the intrinsic TDLN-tropic migration of DCs for targeted delivery and release of antibodies in TDLNs.
• Assessing the suppression of breast cancer growth in a mouse model.

Main Results:

• The DC-based platform successfully delivered anti-PD-L1 antibodies to TDLNs.
• Antigen-loaded DCs enhanced T cell immunity, while PD-L1 blockade augmented systemic antitumor immunity.
• This approach led to significant suppression of breast cancer growth, with 83.3% of treated mice becoming tumor-free.

Conclusions:

• Harnessing DC tropism offers a novel strategy for TDLN-targeted PD-L1 blockade.
• Combining DC-based vaccination with ICB therapy presents new translational opportunities for cancer treatment.